COMP <GO>
LH vs ABBV // NET PROFIT MARGIN
Labcorp Holdings Inc. (NYSE) VS. AbbVie Inc. (NYSE) • 15-METRIC TALLY: LH 6
— ABBV 9
▲ NET PROFIT MARGIN LEADER: ABBV
LAST: $361.39 (-1.84%) • MKT CAP: $29.86B
net-margins
6.30%
LAST: $294.89 (+1.41%) • MKT CAP: $513.86B
net-margins
6.90%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (LH VS. ABBV)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | LH | ABBV | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 28.80% | 70.20% | -41.40 | ABBV | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 8.30% | 29.00% | -20.70 | ABBV | /roic <GO> |
| EV/EBITDA & P/E Valuation | 19.6x | 33.3x | -13.70 | LH | /valuation <GO> |
| Free Cash Flow Yield | 4.04% | 3.47% | +0.57 | LH | /fcf-yield <GO> |
| Operating Margin | 9.90% | 24.60% | -14.70 | ABBV | /operating-margins <GO> |
| Net Profit Margin ACTIVE | 6.30% | 6.90% | -0.60 | ABBV | /net-margins <GO> |
| Revenue Growth (YoY) | 7.20% | 8.60% | -1.40 | ABBV | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.81% | 2.27% | -1.46 | ABBV | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 3.58 | 5.33 | -1.75 | ABBV | /balance-sheet <GO> |
| Piotroski F-Score Quality | 8/9 | 7/9 | +1.00 | LH | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | 6.80% | 7.40% | -0.60 | LH | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 74.5 | 72.8 | +1.76 | LH | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 0.96 | 1.15 | -0.19 | ABBV | /macro-sensitivity <GO> |
| Forward P/E Multiple | 31.6x | 113.1x | -81.50 | LH | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $29.86B | $513.86B | -$484.00B | ABBV | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | LH REV | ABBV REV | LH GROSS % | ABBV GROSS % | LH FCF | ABBV FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $13.95B | $61.16B | 28.8% | 70.2% | $1.21B | $17.82B |
| FY 2024 | $13.01B | $56.33B | 27.9% | 70.0% | $1.10B | $17.83B |
| FY 2023 | $12.16B | $54.32B | 44.0% | 44.0% | $780.4M | $20.39B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
LH // BETA 0.96
ABBV // BETA 1.15